Results 251 to 260 of about 215,808 (286)
Some of the next articles are maybe not open access.
Clinical Pharmacokinetics, 1999
The application of population approaches to drug development is recommended in several US Food and Drug Administration (FDA) guidance documents. Population pharmacokinetic (and pharmacodynamic) techniques enable identification of the sources of inter- and intra-individual variability that impinge upon drug safety and efficacy.
H, Sun +11 more
openaire +2 more sources
The application of population approaches to drug development is recommended in several US Food and Drug Administration (FDA) guidance documents. Population pharmacokinetic (and pharmacodynamic) techniques enable identification of the sources of inter- and intra-individual variability that impinge upon drug safety and efficacy.
H, Sun +11 more
openaire +2 more sources
The Journal of Clinical Pharmacology, 1988
The major strength of the population analysis approach is that useful information can be extracted from sparse data using blood samples and pharmacologic monitoring during routine safety and efficacy studies conducted during the development of a drug product.
openaire +2 more sources
The major strength of the population analysis approach is that useful information can be extracted from sparse data using blood samples and pharmacologic monitoring during routine safety and efficacy studies conducted during the development of a drug product.
openaire +2 more sources
Population pharmacokinetics of ramosetron
Journal of Pharmacokinetics and Pharmacodynamics, 2015Ramosetron is a selective serotonergic 5-hydroxy-tryptamine receptor 3 antagonist that is used to prevent and treat postoperative nausea and vomiting. This study aimed to characterize the population pharmacokinetics of ramosetron in patients undergoing surgery with general anesthesia.
Seong Heon Lee +3 more
openaire +2 more sources
Population pharmacokinetics of oxaliplatin
Cancer Chemotherapy and Pharmacology, 2002The objective of this study was to explore correlations between a variety of covariates and oxaliplatin ultrafilterable and blood pharmacokinetic parameters. Data from 40 patients receiving oxaliplatin combined with 5-fluorouracil and levofolinic acid as standard treatment for advanced colorectal cancer were analysed. Plasma ultrafilterable, blood, and
Jean-Pierre, Delord +7 more
openaire +2 more sources
Clinical Pharmacokinetics, 1986
Good therapeutic practice should always be based on an understanding of pharmacokinetic variability. This ensures that dosage adjustments can be made to accommodate differences in pharmacokinetics due to genetic, environmental, physiological or pathological factors.
B, Whiting, A W, Kelman, J, Grevel
openaire +2 more sources
Good therapeutic practice should always be based on an understanding of pharmacokinetic variability. This ensures that dosage adjustments can be made to accommodate differences in pharmacokinetics due to genetic, environmental, physiological or pathological factors.
B, Whiting, A W, Kelman, J, Grevel
openaire +2 more sources
Population Pharmacokinetics of Lamotrigine
Therapeutic Drug Monitoring, 2001The present study estimated the population pharmacokinetics of lamotrigine in patients receiving oral lamotrigine therapy with drug concentration monitoring, and determined intersubject and intrasubject variability. A total of 129 patients were analyzed from two clinical sites. Of these, 124 patients provided sparse data (198 concentration-time points);
Chan, V., Morris, R., Ilet, K., Tett, S.
openaire +3 more sources
Pharmacokinetics in special populations
Drug Metabolism Reviews, 2009Pharmacokinetics are typically dependent on a variety of physiological variables (e.g., age, ethnicity, or pregnancy) or pathological conditions (e.g., renal and hepatic insufficiency, cardiac dysfunction, obesity, etc.). The influence of some of these conditions has not always been thoroughly assessed in the clinical studies of antiallergic drugs ...
Italo, Poggesi +5 more
openaire +2 more sources
Population Pharmacokinetics of Terfenadine
Pharmaceutical Research, 1996After oral administration of terfenadine, plasma concentrations of the parent drug are usually below the limits of quantitation of conventional analytical methods because of extensive first-pass metabolism. Data are usually reported on the carboxylic acid metabolite (M1) but there are no published reports of pharmacokinetic parameters for terfenadine ...
R L, Lalonde, D, Lessard, J, Gaudreault
openaire +2 more sources